当地时间 2025 年 7 月 28 日，Ascendis Pharma 公司宣布，美国 FDA 已批准其长效生长激素药物 TransCon hGH（lonapegsomatropin-tcgd）的补充生物制品许可申请（sBLA），用于治疗成人生长激素缺乏症（GHD）。此前该药已获得 FDA 批准用于治疗儿童 GHD 患者。截图来源：Ascendis官网TransCon hGH 是依托 ...
Source Link当地时间 2025 年 7 月 28 日，Ascendis Pharma 公司宣布，美国 FDA 已批准其长效生长激素药物 TransCon hGH（lonapegsomatropin-tcgd）的补充生物制品许可申请（sBLA），用于治疗成人生长激素缺乏症（GHD）。此前该药已获得 FDA 批准用于治疗儿童 GHD 患者。截图来源：Ascendis官网TransCon hGH 是依托 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.